Table 1.

Demographics, mechanism of injury, admission physiology, and injury severity of patients on novel oral anticoagulants

	Dabigatran	Rivaroxaban	Apixaban	Pvalues
n	50	123	34
Age (SD)	79 (12)	74 (16)	80 (11)	0.137
Female (%)	52	46	56	0.493
Renal failure (%)	0 (0)	1 (1)	0 (0)	0.710
Cirrhosis (%)	1 (2)	2 (2)	0 (0)	0.729
Race* (%)				0.777
Black	0	1	0
Asian	2	1	0
Hispanic	8	7	3
Non-Hispanic white	84	86	97
Mechanism (%)				0.843
Fall	70	74	74
Motor vehicle accident	14	16	18
Found down	6	2	0
Auto vs. pedestrian	4	2	0
GCS≤8 (%)	4	4	3	0.954
Shock (SBP<90) (%)	4	7	0	0.279
ISS median (IQR)†	9 (4–13)	5 (4–10)	6 (4–10)	0.834
ISS≥10† (%)	42	36	41	0.737
Reversed (%)	7 (14)	31 (25)	6 (18)	0.225

Missing data <1% unless specifically noted in the table. Data previously presented.²²

For Renal Failure and Cirrhosis both the number of patients as well as percent (in parentheses) of the population with the comorbidity are presented.

Values in bold signify number of patients and percent of population in parentheses.

*Race: missing/other: 9 (4%).

†ISS: missing 3 (1.5%).

GCS, Glasgow Coma Scale; ISS, Injury Severity Score; SBP, systolic blood pressure.